Discover how rimegepant (Nurtec ODT) works for both migraine treatment and prevention. Learn about the approved age range, ...

NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2026 of $0.235 per Class A ...

Even with a lower-than-expected inflation reading Thursday, the cost of everyday goods and services remains much higher than it was at the start of the decade. Prices rose 2.7% over the past year, ...

Commercial real estate has had a rough go after gaining momentum coming out of the pandemic. October was the first month of negative year-over-year transaction volume growth in the sector in nearly ...

Poor commercial real estate. Fewer investors want to touch it after being burned by falling property values in recent years. They have better options anyway. Why settle for 7% annual returns on real ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The bank's commercial lending ...

Pfizer's Q3 earnings fell, but the company still raised its full-year earnings guidance. Major cost reductions remain on track, which should significantly boost the drugmaker's bottom line. Pfizer's ...

Nurtec ODT (rimegepant) is not used to treat tension headaches because of the way the drug works. Nurtec ODT targets a protein involved in migraine, not tension headaches. Doctors may prescribe Nurtec ...

Royalty Pharma Plc (NASDAQ:RPRX) is one of the top most undervalued biotech stocks to buy now. In a report released on August 7, Terence Flynn from Morgan Stanley maintained a Buy rating on Royalty ...

Income investors seeking juicy dividends should check out these healthcare stocks. The healthcare sector has long been a favorite for income investors -- and for good reason. Many healthcare stocks ...